{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:12:43Z","timestamp":1788592363485,"version":"build-2803163510"},"reference-count":46,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"abstract":"Evidence on the efficacy and safety of medicines supporting marketing authorization is largely derived from randomized controlled trials, yet these trials often exclude populations likely to use the medications in clinical practice. This study assessed eligibility of special populations, defined as pregnant and breast\u2010feeding individuals, elderly individuals, and individuals with comorbidities, in pivotal clinical trials supporting centrally authorized products in the European Union between 2022 and 2024. It also examined whether exclusions of the special populations were supported by scientific justifications in the form of prior clinical or nonclinical evidence documented in regulatory sources. Among 24 products supported by 44 pivotal trials, pregnant and breast\u2010feeding individuals were most frequently excluded (16\/24 products), followed by individuals with cardiovascular disease or hepatic impairment (13\/24 products) and renal impairment (10\/24 products). Exclusion of elderly individuals based on age alone was uncommon (1\/24 products). Of the 24 products, 15 excluded more than one special population. While exclusions of pregnant and breast\u2010feeding individuals were largely supported by preclinical evidence suggesting safety concerns, those related to comorbidities were often not accompanied by prior evidence justifying exclusions. Broad exclusion criteria based on investigator judgment were also common. These findings reveal variation in how exclusion criteria are justified across special populations in regulatory documentation and suggest an opportunity for greater transparency and consistency in documenting the scientific and ethical justification for these criteria in clinical trials.<\/jats:p>","DOI":"10.1002\/cpt.70475","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:51:36Z","timestamp":1788591096000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Special Populations in Pivotal Clinical Trials: Eligibility and Supporting Evidence for Exclusion in\n EMA<\/scp>\n \u2010Authorised Medicines"],"prefix":"10.1002","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-4308-8164","authenticated-orcid":false,"given":"Maja J.","family":"J\u00f8rgensen","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Copenhagen Centre for Regulatory Science and Real\u2010World Studies University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5900-540X","authenticated-orcid":false,"given":"D\u00e9bora D.","family":"Gr\u00e4f","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Copenhagen Centre for Regulatory Science and Real\u2010World Studies University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7916-3915","authenticated-orcid":false,"given":"Christine E.","family":"Hallgreen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Copenhagen Centre for Regulatory Science and Real\u2010World Studies University of Copenhagen Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"e_1_2_12_1_1","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1056\/NEJMms1604593","article-title":"Assessing the gold standard\u2014lessons from the history of RCTs","volume":"374","author":"Bothwell L.E.","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_2_1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy\u2010Martin T.","year":"2015","journal-title":"Trials"},{"key":"e_1_2_12_3_1","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.3694","article-title":"Populations addressed in vaccines approved via the European medicines agency","volume":"118","author":"Gr\u00e4f D.D.","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"e_1_2_12_4_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajogmf.2022.100700","article-title":"Inclusion of pregnant and breastfeeding women in nonobstetrical randomized controlled trials","volume":"4","author":"Jorgensen S.C.J.","year":"2022","journal-title":"Am. J. Obstet. Gynecol. MFM"},{"key":"e_1_2_12_5_1","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1002\/bcp.70061","article-title":"Analysis of 4616 clinical trial initial submissions received by the medicines and healthcare products regulatory agency between February 2019 and October 2023","volume":"91","author":"Manfrin A.","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"e_1_2_12_6_1","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1001\/archinternmed.2011.31","article-title":"The persistent exclusion of older patients from ongoing clinical trials regarding heart failure","volume":"171","author":"Cherubini A.","year":"2011","journal-title":"Arch. Intern. Med."},{"key":"e_1_2_12_7_1","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/jgs.15786","article-title":"Adequacy of inclusion of older adults in NIH\u2010funded phase III clinical trials","volume":"67","author":"Lockett J.","year":"2019","journal-title":"J. Am. Geriatr. Soc."},{"key":"e_1_2_12_8_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cct.2021.106515","article-title":"Eligibility criteria and clinical trials: an FDA perspective","volume":"109","author":"Duggal M.","year":"2021","journal-title":"Contemp. Clin. Trials"},{"key":"e_1_2_12_9_1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high\u2010impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall H.G.C.","year":"2007","journal-title":"JAMA"},{"key":"e_1_2_12_10_1","doi-asserted-by":"crossref","first-page":"e240427","DOI":"10.1001\/jamanetworkopen.2024.0427","article-title":"Representation of patients with chronic kidney disease in clinical trials of cardiovascular disease medications: a systematic review","volume":"7","author":"Colombijn J.M.T.","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"e_1_2_12_11_1","doi-asserted-by":"crossref","first-page":"102490","DOI":"10.1016\/j.jchf.2025.03.036","article-title":"Exclusion of liver disease and underutilization of liver\u2010specific endpoints in heart failure trials","volume":"13","author":"Khan M.S.","year":"2025","journal-title":"JACC Heart Fail."},{"key":"e_1_2_12_12_1","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s13555-025-01633-6","article-title":"Clinical trial eligibility in atopic dermatitis: data from a large real\u2010world international cohort","volume":"16","author":"Alvarenga J.M.","year":"2026","journal-title":"Dermatol. Ther."},{"key":"e_1_2_12_13_1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3109\/10601333.2015.1001900","article-title":"Special population considerations and regulatory affairs for clinical research","volume":"32","author":"Grimsrud K.N.","year":"2015","journal-title":"Clin. Res. Regul. Aff."},{"key":"e_1_2_12_14_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjph-2025-003423","article-title":"Bridging disciplinary siloes: a scoping review on the inclusion and exclusion of pregnant and lactating populations in clinical research","volume":"4","author":"Shankar M.","year":"2026","journal-title":"BMJ Public Health"},{"key":"e_1_2_12_15_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.arr.2016.02.004","article-title":"Regulatory development of geriatric medicines: to GIP or not to GIP?","volume":"27","author":"De Spiegeleer B.","year":"2016","journal-title":"Ageing Res. Rev."},{"key":"e_1_2_12_16_1","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ajog.2022.07.037","article-title":"Scientific, ethical, and legal considerations for the inclusion of pregnant people in clinical trials","volume":"227","author":"Sewell C.A.","year":"2022","journal-title":"Am. J. Obstet. Gynecol."},{"key":"e_1_2_12_17_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials E21 (Draft Version) (2025)."},{"key":"e_1_2_12_18_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH).Studies in Support of Special Populations: Geriatrics E7. ICH (1993)."},{"key":"e_1_2_12_19_1","unstructured":"U.S. Food and Drug Administration.Enhancing the diversity of clinical trial populations \u2014 eligibility criteria Enrollment Practices and Trial Designs Guidance for Industry (2025)."},{"key":"e_1_2_12_20_1","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.General Considerations for Clinical Studies E8. Report No.: E8(R1) (2021)."},{"key":"e_1_2_12_21_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ijrobp.2022.10.026","article-title":"Carrots or sticks: an industry perspective on the significance of regulatory guidance in promoting participant diversity in clinical trials","volume":"116","author":"Peters U.","year":"2023","journal-title":"Int. J. Radiation Oncol."},{"key":"e_1_2_12_22_1","unstructured":"European Medicines Agency.Scientific guidelines. Accessed 18 May 2026."},{"key":"e_1_2_12_23_1","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1377\/hlthaff.2022.00520","article-title":"Excluding people with disabilities from clinical research: eligibility criteria lack clarity and justification","volume":"41","author":"DeCormier Plosky W.","year":"2022","journal-title":"Health Aff."},{"key":"e_1_2_12_24_1","unstructured":"World Health Organization.Anatomical Therapeutic Chemical (ATC) Classification. Accessed 13 June 2026."},{"key":"e_1_2_12_25_1","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(25)01637-X","article-title":"Burden of 375 diseases and injuries, risk\u2010attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990\u20132023: a systematic analysis for the global burden of disease study 2023","volume":"406","author":"Hay S.I.","year":"2025","journal-title":"Lancet"},{"key":"e_1_2_12_26_1","unstructured":"International Council for Harmonisation of technical requirements for Pharmaceuticals for Human use (ICH).MedDRA \u2013 Medical Dictionary for Regulatory Activities. Accessed 13 June 2026."},{"key":"e_1_2_12_27_1","unstructured":"European medicines agency.Assessment report Tecovirimat SIGANov. Report No.: EMA\/703119\/2021. (2021). Accessed 3 June 2026."},{"key":"e_1_2_12_28_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13063-017-2402-9","article-title":"Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach","volume":"19","author":"Graaf R.","year":"2018","journal-title":"Trials"},{"key":"e_1_2_12_29_1","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3138\/ijfab.1.2.5","article-title":"The second wave: toward responsible inclusion of pregnant women in research","volume":"1","author":"Lyerly A.D.","year":"2008","journal-title":"Int. J. Fem. Approaches Bioeth."},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2017.74.4102","article-title":"Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology\u2013Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group","volume":"35","author":"Lichtman S.M.","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300236"},{"key":"e_1_2_12_32_1","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s40520-023-02380-4","article-title":"Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID\u201019 vaccine trials before and after the COVID\u201019 pandemic","volume":"35","author":"Bukan K.","year":"2023","journal-title":"Aging Clin. Exp. Res."},{"key":"e_1_2_12_33_1","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s11606-010-1629-x","article-title":"Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials","volume":"26","author":"Zulman D.M.","year":"2011","journal-title":"J. Gen. Intern. Med."},{"key":"e_1_2_12_34_1","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/ije\/dyt103","article-title":"Commentary: representativeness is usually not necessary and often should be avoided","volume":"42","author":"Richiardi L.","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"e_1_2_12_35_1","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/ije\/dys223","article-title":"Why representativeness should be avoided","volume":"42","author":"Rothman K.J.","year":"2013","journal-title":"Int. J. Epidemiol."},{"key":"e_1_2_12_36_1","article-title":"The silent exclusion: rethinking eligibility and generalizability in clinical trials","volume":"61","author":"Jensen J.\u2010U.","year":"2025","journal-title":"Lancet Reg Health West Pac."},{"key":"e_1_2_12_37_1","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJMp2209043","article-title":"New Federal Incentives for diversity in clinical trials","volume":"387","author":"Hwang T.J.","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_38_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cto whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell P.M.","year":"2005","journal-title":"The Lancet."},{"key":"e_1_2_12_39_1","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","article-title":"Real\u2010world evidence\u2014what is it and what can it tell us?","volume":"375","author":"Sherman R.","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"e_1_2_12_40_1","volume-title":"Framework for FDA's Real\u2010World Evidence Program","author":"U.S. Food and Drug Administration","year":"2018"},{"key":"e_1_2_12_41_1","volume-title":"Reflection paper on use of real\u2010world data in noninterventional studies to generate real\u2010world evidence for regulatory purposes","author":"European Medicines Agency","year":"2025"},{"key":"e_1_2_12_42_1","unstructured":"European Medicines Agency.Real\u2010world evidence provided by EMA.Amsterdam:European Medicines Agency;2024"},{"key":"e_1_2_12_43_1","unstructured":"European Medicines Agency.EMA Regulatory Science to 2025.Amsterdam:European Medicines Agency;2020"},{"key":"e_1_2_12_44_1","unstructured":"Paediatric investigation plans | European medicines agency (EMA) (2015). Accessed 5 June 2026."},{"key":"e_1_2_12_45_1","unstructured":"U.S. Food and Drug Administration.Pediatric Research Equity Act | PREAU.S. Food and Drug Administration (2024)."},{"key":"e_1_2_12_46_1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/978-3-319-26512-4_4","volume-title":"Clin Res Involv Pregnant Women","author":"Kaposy C.","year":"2016"}],"container-title":["Clinical Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70475","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.70475","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.70475","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T06:51:47Z","timestamp":1788591107000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.70475"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":46,"alternative-id":["10.1002\/cpt.70475"],"URL":"https:\/\/doi.org\/10.1002\/cpt.70475","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"assertion":[{"value":"2026-06-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"cpt.70475"}}